WO2001005408A8 - Fat-binding polymers, optionally combined with lipase inhibitors - Google Patents

Fat-binding polymers, optionally combined with lipase inhibitors

Info

Publication number
WO2001005408A8
WO2001005408A8 PCT/US1999/015958 US9915958W WO0105408A8 WO 2001005408 A8 WO2001005408 A8 WO 2001005408A8 US 9915958 W US9915958 W US 9915958W WO 0105408 A8 WO0105408 A8 WO 0105408A8
Authority
WO
WIPO (PCT)
Prior art keywords
fat
binding polymers
lipase inhibitors
polymers
binding
Prior art date
Application number
PCT/US1999/015958
Other languages
French (fr)
Other versions
WO2001005408A1 (en
Inventor
Thomas Henry Jozefiak
W Harry Mandeville Iii
Stephen Randall Holmes-Farley
Chad Cori Huval
Venkata R Garigapati
Keith K Shackett
Danny Concagh
Original Assignee
Geltex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geltex Pharma Inc filed Critical Geltex Pharma Inc
Priority to NZ516554A priority Critical patent/NZ516554A/en
Priority to AU49957/99A priority patent/AU774636B2/en
Priority to MXPA02000492A priority patent/MXPA02000492A/en
Priority to IL14736199A priority patent/IL147361A0/en
Priority to PCT/US1999/015958 priority patent/WO2001005408A1/en
Priority to EP99934037A priority patent/EP1196181A1/en
Priority to CA002379308A priority patent/CA2379308A1/en
Publication of WO2001005408A1 publication Critical patent/WO2001005408A1/en
Publication of WO2001005408A8 publication Critical patent/WO2001005408A8/en
Priority to HK02107346.4A priority patent/HK1046092A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Abstract

The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin.
PCT/US1999/015958 1999-07-14 1999-07-14 Fat-binding polymers, optionally combined with lipase inhibitors WO2001005408A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
NZ516554A NZ516554A (en) 1999-07-14 1999-07-14 Fat-binding polymers, optionally combined with lipase inhibitors
AU49957/99A AU774636B2 (en) 1999-07-14 1999-07-14 Fat-binding polymers, optionally combined with lipase inhibitors
MXPA02000492A MXPA02000492A (en) 1999-07-14 1999-07-14 Fat-binding polymers, optionally combined with cipase inhibitors.
IL14736199A IL147361A0 (en) 1999-07-14 1999-07-14 Fat-binding polymers, optionally combined with lipase inhibitors
PCT/US1999/015958 WO2001005408A1 (en) 1999-07-14 1999-07-14 Fat-binding polymers, optionally combined with lipase inhibitors
EP99934037A EP1196181A1 (en) 1999-07-14 1999-07-14 Fat-binding polymers, optionally combined with lipase inhibitors
CA002379308A CA2379308A1 (en) 1999-07-14 1999-07-14 Fat-binding polymers, optionally combined with lipase inhibitors
HK02107346.4A HK1046092A1 (en) 1999-07-14 2002-10-08 Fat-binding polymers, optionally combined with lipase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/015958 WO2001005408A1 (en) 1999-07-14 1999-07-14 Fat-binding polymers, optionally combined with lipase inhibitors

Publications (2)

Publication Number Publication Date
WO2001005408A1 WO2001005408A1 (en) 2001-01-25
WO2001005408A8 true WO2001005408A8 (en) 2001-07-19

Family

ID=22273208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/015958 WO2001005408A1 (en) 1999-07-14 1999-07-14 Fat-binding polymers, optionally combined with lipase inhibitors

Country Status (7)

Country Link
EP (1) EP1196181A1 (en)
AU (1) AU774636B2 (en)
CA (1) CA2379308A1 (en)
HK (1) HK1046092A1 (en)
IL (1) IL147361A0 (en)
MX (1) MXPA02000492A (en)
WO (1) WO2001005408A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049345B2 (en) * 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
CA2778802A1 (en) * 2009-11-17 2011-05-26 Dow Global Technologies Llc Amine adducts
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
IT1404163B1 (en) * 2011-02-01 2013-11-15 Chemi Spa PROCESS FOR THE PREPARATION OF RETICULATED POLYALLYLAMINS OR THEIR PHARMACEUTICAL ACCEPTABLE SALTS
PT3188717T (en) 2014-08-11 2020-04-02 Perora Gmbh Formulation comprising particles
RU2690672C2 (en) 2014-08-11 2019-06-05 Перора Гмбх Method of inducing satiety
WO2017005890A1 (en) 2015-07-07 2017-01-12 Perora Gmbh Method of inducing satiety
CA2989511A1 (en) 2015-07-07 2017-01-12 Perora Gmbh Edible composition comprising a polysaccharide and a lipid
EP3455283B1 (en) * 2016-05-10 2020-06-10 Dow Silicones Corporation Silicone block copolymer having an aminofunctional endblocking group and method for its preparation and use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211765A (en) * 1971-10-12 1980-07-08 Monsanto Company Method for controlling obesity
US4432968A (en) * 1980-10-20 1984-02-21 The Dow Chemical Company Weight control with fat imbibing polymers
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US4759923A (en) * 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
EP0706399A4 (en) * 1993-06-02 1998-08-12 Geltex Pharma Inc Compositions and process for removing bile salts
US5624963A (en) * 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5900475A (en) * 1994-06-10 1999-05-04 Geltex Pharmaceuticals, Inc. Hydrophobic sequestrant for cholesterol depletion
JPH07316061A (en) * 1994-05-23 1995-12-05 Sekisui Chem Co Ltd Cholesterol lowering agent
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US6203785B1 (en) * 1996-12-30 2001-03-20 Geltex Pharmaceuticals, Inc. Poly(diallylamine)-based bile acid sequestrants
US5925379A (en) * 1997-03-27 1999-07-20 Geltex Pharmaceuticals, Inc. Interpenetrating polymer networks for sequestration of bile acids
JP4870869B2 (en) * 1997-07-31 2012-02-08 コス・ライフ・サイエンシズ・インコーポレイテッド Combination of HMG-CoA reductase inhibitor and nicotinic acid compound, and method for treating hyperlipidemia once a day at night
US5900233A (en) * 1997-10-16 1999-05-04 Day; Charles E. Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome
RU2222335C2 (en) * 1998-01-09 2004-01-27 Джензайм Корпорейшн Fat-binding polymers

Also Published As

Publication number Publication date
MXPA02000492A (en) 2002-07-02
CA2379308A1 (en) 2001-01-25
HK1046092A1 (en) 2002-12-27
AU4995799A (en) 2001-02-05
WO2001005408A1 (en) 2001-01-25
EP1196181A1 (en) 2002-04-17
AU774636B2 (en) 2004-07-01
IL147361A0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
UA88270C2 (en) Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2003024387A3 (en) Method and pharmaceutical composition for treating inflammation
WO2006073786A3 (en) Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
WO2004028570A3 (en) A method for treating severe tinnitus
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2003000242A3 (en) Method for the treatment of lymphedema using guaifenesin
EP1702618A3 (en) Compositions and uses of et743 in combination therapy for treating cancer
WO2001005408A8 (en) Fat-binding polymers, optionally combined with lipase inhibitors
WO1999034787A3 (en) Fat-binding polymers
CA2401000A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
GB0020504D0 (en) Therapeutic method
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
WO2002065989A3 (en) Aminoglycoside treatment for lysosomal storage diseases
GB0201367D0 (en) Composition
WO2001054678A3 (en) Combination therapy for cancer
CZ223199A3 (en) Use of comt inhibitors or pharmaceutically acceptable salts or esters thereof for preparing a medicament for prevention diabetic vascular dysfunctions
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
EP1512413A3 (en) Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer
MD1469G2 (en) Method of treatment of the burn shock
WO2004021973A3 (en) Pravastatin pharmaceutical formulations and methods of their use
WO2004035030A3 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
WO2003072737A3 (en) Biological inhibitions induced by contact inhibitory factor
WO2000023058A3 (en) Use of an antianaerobic-bacterial or/and antiprotozoal agent (preferably metronidazole) in the manufacture of a medicament for the treatment of haemorrhoids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: PUBLISHED TITLE REPLACED BY CORRECT TITLE

WWE Wipo information: entry into national phase

Ref document number: 49957/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 516554

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/000492

Country of ref document: MX

Ref document number: 2379308

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999934037

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999934037

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 516554

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 516554

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 49957/99

Country of ref document: AU